poisar

Stock

Veracyte, Inc. VCYT

$46.32-22.52%

Overview

VCYT market data

Price History

VCYT price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
41.34
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$0.82
Diluted earnings per share over the trailing twelve months.
Beta
1.94
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$22.92 – $60.91
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $3.6K · P/B 2.54 · P/S 6.72.

Company News

10 captured
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga · Jul 31, 2026, 12:02 PM
Needham Maintains Buy on Veracyte, Raises Price Target to $69Benzinga · Jul 31, 2026, 9:45 AM
8-K filing — VERACYTE, INC. (VCYT)SEC EDGAR · Jul 30, 2026, 8:18 PM
Veracyte Raises FY2026 Sales Guidance from $582.000M-$592.000M to $590.000M-$596.000M vs $586.445M EstBenzinga · Jul 30, 2026, 8:06 PM
Veracyte Q2 Adj. EPS $0.54 Beats $0.24 Estimate, Sales $150.321M Beat $144.554M EstimateBenzinga · Jul 30, 2026, 8:05 PM
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayBenzinga · Jul 15, 2026, 10:59 AM
Piper Sandler Initiates Coverage On Veracyte with Overweight Rating, Announces Price Target of $66Benzinga · Jul 15, 2026, 9:11 AM
Canaccord Genuity Maintains Hold on Veracyte, Raises Price Target to $60Benzinga · Jul 14, 2026, 12:03 PM
Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $47Benzinga · Jul 9, 2026, 5:35 PM
Guggenheim Maintains Buy on Veracyte, Raises Price Target to $65Benzinga · Jun 29, 2026, 2:10 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock